ATE490779T1 - Y4-selektive rezeptoragonist für therapeutische interventionen - Google Patents

Y4-selektive rezeptoragonist für therapeutische interventionen

Info

Publication number: ATE490779T1
Authority: AT; Austria
Prior art keywords: receptor agonist; therapeutic interventions; selective receptor; selective; receptors
Prior art date: 2004-03-17

Application number

AT05716258T

Other languages

English (en)

Inventor

Thue Schwartz

Original Assignee

7Tm Pharma As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-03-17

Filing date

2005-03-17

Publication date

2010-12-15

2005-02-14 Priority claimed from GB0503110A external-priority patent/GB0503110D0/en

2005-03-17 Application filed by 7Tm Pharma As filed Critical 7Tm Pharma As

2010-12-15 Application granted granted Critical

2010-12-15 Publication of ATE490779T1 publication Critical patent/ATE490779T1/de

Links

239000000018 receptor agonist Substances 0.000 title abstract 3
229940044601 receptor agonist Drugs 0.000 title abstract 3
230000001225 therapeutic effect Effects 0.000 title 1
102000028435 Neuropeptide Y4 receptor Human genes 0.000 abstract 2
108010002245 Neuropeptide Y4 receptor Proteins 0.000 abstract 2
102100038991 Neuropeptide Y receptor type 2 Human genes 0.000 abstract 1
101710197945 Neuropeptide Y receptor type 2 Proteins 0.000 abstract 1
102000018886 Pancreatic Polypeptide Human genes 0.000 abstract 1
108700020479 Pancreatic hormone Proteins 0.000 abstract 1
230000004913 activation Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hematology (AREA)
Obesity (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Immunology (AREA)
Biophysics (AREA)
Toxicology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Reproductive Health (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Epidemiology (AREA)
Cell Biology (AREA)
Otolaryngology (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)

AT05716258T 2004-03-17 2005-03-17 Y4-selektive rezeptoragonist für therapeutische interventionen ATE490779T1 (de)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
DKPA200400436		2004-03-17
US55893204P	2004-04-01	2004-04-01
US58596404P	2004-07-06	2004-07-06
GB0503110A GB0503110D0 (de)	2005-02-14	2005-02-14
PCT/EP2005/002983 WO2005089786A2 (en)	2004-03-17	2005-03-17	Y4 selective receptor agonists for therapeutic interventions

Publications (1)

Publication Number	Publication Date
ATE490779T1 true ATE490779T1 (de)	2010-12-15

Family

ID=43302286

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT05716258T ATE490779T1 (de)	2004-03-17	2005-03-17	Y4-selektive rezeptoragonist für therapeutische interventionen
AT09075024T ATE519495T1 (de)	2004-03-17	2005-03-17	Y4-selektiver rezeptoragonist pp2-36 für therapeutische eingriffe

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT09075024T ATE519495T1 (de)	2004-03-17	2005-03-17	Y4-selektiver rezeptoragonist pp2-36 für therapeutische eingriffe

Country Status (15)

Country	Link
US (1)	US20080269114A1 (de)
EP (3)	EP2060266B1 (de)
JP (1)	JP2007529463A (de)
AT (2)	ATE490779T1 (de)
AU (1)	AU2005224028B2 (de)
BR (1)	BRPI0508935A (de)
CA (1)	CA2560174A1 (de)
DE (1)	DE602005025199D1 (de)
DK (1)	DK2060266T3 (de)
EA (1)	EA012071B1 (de)
GB (1)	GB2427551B (de)
IL (1)	IL177681A0 (de)
MX (1)	MXPA06010345A (de)
PL (1)	PL2060266T3 (de)
WO (1)	WO2005089786A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2005224027B2 (en) *	2004-03-17	2011-05-26	7Tm Pharma A/S	Y2/Y4 selective receptor agonists for therapeutic interventions
CN100425282C (zh) *	2004-03-17	2008-10-15	7Tm制药联合股份有限公司	用于治疗性干预的y2/y4选择性受体激动剂
WO2006091505A2 (en) *	2005-02-24	2006-08-31	Bayer Pharmaceuticals Corporation	Neuropeptide y receptor agonists
AU2005335905C1 (en)	2005-08-26	2011-12-22	Abbvie Inc.	Therapeutically active alpha-MSH analogues
EA200800875A1 (ru) *	2005-09-21	2008-08-29	7ТиЭм ФАРМА А/С	Рецепторные агонисты, селективные к y2 рецептору, для терапевтического воздействия
EA200800874A1 (ru) *	2005-09-21	2008-08-29	7ТиЭм ФАРМА А/С	Рецепторные агонисты, селективные к y4 рецептору, для терапевтического воздействия
EP1990427A4 (de) *	2006-02-24	2009-04-29	Banyu Pharma Co Ltd	Npy y4-agonist als therapeutikum gegen eine von einer fehlfunktion des darmtrakts begleitete krankheit
CN101668759A (zh)	2007-05-04	2010-03-10	百时美施贵宝公司	[6,5]-双环gpr119g蛋白-偶合受体激动剂
ES2388967T3 (es)	2007-05-04	2012-10-22	Bristol-Myers Squibb Company	Agonistas [6,6]- y [6,7]-bicíclicos del receptor GPR119 acoplado a la proteína G
CN101970475A (zh) *	2007-07-09	2011-02-09	帝国改革有限公司	人类胰多肽(hpp)类似物及其对摄食行为的作用
TW200904440A (en)	2007-07-17	2009-02-01	Bristol Myers Squibb Co	Method for modulating GPR119 G protein-coupled receptor and selected compounds
WO2009138511A1 (en) *	2008-05-16	2009-11-19	Novo Nordisk A/S	Long-acting y2 and/or y4 receptor agonists
TW201006821A (en)	2008-07-16	2010-02-16	Bristol Myers Squibb Co	Pyridone and pyridazone analogues as GPR119 modulators
GB0817067D0 (en) *	2008-09-18	2008-10-22	7Tm Pharma As	Intestinal treatment
US9023408B2 (en)	2009-03-04	2015-05-05	Meyer Nutriceuticals Llc	Composition and method for control of diabetes
GB201001333D0 (en)	2010-01-27	2010-03-17	Imp Innovations Ltd	Novel compounds and their effects on feeding behaviour
EA201270755A1 (ru)	2010-04-08	2013-03-29	Бристол-Майерс Сквибб Компани	Аналоги пиримидинилпиперидинилоксипиридинона в качестве модуляторов рецептора gpr119
WO2011140161A1 (en)	2010-05-06	2011-11-10	Bristol-Myers Squibb Company	Benzofuranyl analogues as gpr119 modulators
WO2011140160A1 (en)	2010-05-06	2011-11-10	Bristol-Myers Squibb Company	Bicyclic heteroaryl compounds as gpr119 modulators
PL2651398T3 (pl)	2010-12-16	2018-05-30	Novo Nordisk A/S	Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
GB201101459D0 (en)	2011-01-27	2011-03-16	Imp Innovations Ltd	Novel compounds and thier effects on fedding behaviour
EP4324475A1 (de)	2012-03-22	2024-02-21	Novo Nordisk A/S	Zusammensetzungen von glp-1-peptiden und herstellung davon
WO2013173198A1 (en)	2012-05-16	2013-11-21	Bristol-Myers Squibb Company	Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
KR20210086717A (ko)	2013-05-02	2021-07-08	노보 노르디스크 에이/에스	Glp-1 화합물의 경구 투여
WO2015061272A1 (en)	2013-10-22	2015-04-30	Bristol-Myers Squibb Company	Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
US10246497B2 (en)	2013-11-15	2019-04-02	Novo Nordisk A/S	Selective PYY compounds and uses thereof
JP6629198B2 (ja)	2013-11-15	2020-01-15	ノヴォノルディスクアー／エス	３５位にβ−ホモアルギニン置換を有するＨＰＹＹ（１−３６）
CA2988500A1 (en)	2015-06-12	2016-12-15	Novo Nordisk A/S	Selective pyy compounds and uses thereof
MA45714A (fr)	2016-07-22	2019-05-29	Bristol Myers Squibb Co	Activateurs de glucokinase et leurs procédés d'utilisation
WO2019149880A1 (en)	2018-02-02	2019-08-08	Novo Nordisk A/S	Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
GB202213305D0 (en) *	2022-09-12	2022-10-26	Univ Ulster	Compositions for use in the treatment of diabetes or obesity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5349052A (en)	1988-10-20	1994-09-20	Royal Free Hospital School Of Medicine	Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5122614A (en)	1989-04-19	1992-06-16	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
EP0871665B1 (de)	1995-03-17	2003-07-23	Novo Nordisk A/S	Insulinabkömmlinge
US5830434A (en) *	1997-02-26	1998-11-03	Medical University Of South Carolina Foundation For Research Development	Methods of treating non-insulin dependent diabetes mellitus with pancreatic polypeptide
AU757658B2 (en)	1998-03-09	2003-02-27	Zealand Pharma A/S	Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US7229966B2 (en) *	2002-12-17	2007-06-12	Nastech Pharmaceutical Company Inc.	Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
CA2510199A1 (en) *	2002-12-17	2004-07-08	Nastech Pharmaceutical Company Inc.	Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
JP5638177B2 (ja) *	2004-02-11	2014-12-10	アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc	膵臓ポリペプチドファミリーモチーフおよびそのモチーフを含むポリペプチド
GB0817067D0 (en) *	2008-09-18	2008-10-22	7Tm Pharma As	Intestinal treatment

2005
- 2005-03-17 PL PL09075024T patent/PL2060266T3/pl unknown
- 2005-03-17 CA CA002560174A patent/CA2560174A1/en not_active Abandoned
- 2005-03-17 AU AU2005224028A patent/AU2005224028B2/en not_active Ceased
- 2005-03-17 EP EP09075024A patent/EP2060266B1/de not_active Expired - Lifetime
- 2005-03-17 WO PCT/EP2005/002983 patent/WO2005089786A2/en not_active Ceased
- 2005-03-17 BR BRPI0508935-2A patent/BRPI0508935A/pt not_active IP Right Cessation
- 2005-03-17 EP EP05716258A patent/EP1729792B1/de not_active Expired - Lifetime
- 2005-03-17 AT AT05716258T patent/ATE490779T1/de not_active IP Right Cessation
- 2005-03-17 EA EA200601720A patent/EA012071B1/ru unknown
- 2005-03-17 MX MXPA06010345A patent/MXPA06010345A/es not_active Application Discontinuation
- 2005-03-17 US US10/592,779 patent/US20080269114A1/en not_active Abandoned
- 2005-03-17 EP EP09075040A patent/EP2057996A3/de not_active Withdrawn
- 2005-03-17 DK DK09075024.1T patent/DK2060266T3/da active
- 2005-03-17 JP JP2007503303A patent/JP2007529463A/ja not_active Ceased
- 2005-03-17 AT AT09075024T patent/ATE519495T1/de not_active IP Right Cessation
- 2005-03-17 DE DE602005025199T patent/DE602005025199D1/de not_active Expired - Lifetime
- 2005-03-17 GB GB0618824A patent/GB2427551B/en not_active Expired - Fee Related
2006
- 2006-08-24 IL IL177681A patent/IL177681A0/en unknown

Also Published As

Publication number	Publication date
US20080269114A1 (en)	2008-10-30
AU2005224028B2 (en)	2011-05-26
ATE519495T1 (de)	2011-08-15
MXPA06010345A (es)	2007-06-19
EA012071B1 (ru)	2009-08-28
EA200601720A1 (ru)	2007-04-27
GB2427551A (en)	2007-01-03
EP2060266B1 (de)	2011-08-10
BRPI0508935A (pt)	2007-09-25
WO2005089786A2 (en)	2005-09-29
EP1729792B1 (de)	2010-12-08
EP2057996A2 (de)	2009-05-13
EP1729792A2 (de)	2006-12-13
PL2060266T3 (pl)	2012-01-31
DK2060266T3 (da)	2011-11-14
CA2560174A1 (en)	2005-09-29
GB0618824D0 (en)	2006-11-01
GB2427551B (en)	2007-05-30
EP2057996A3 (de)	2009-11-04
EP2060266A1 (de)	2009-05-20
DE602005025199D1 (en)	2011-01-20
IL177681A0 (en)	2006-12-31
JP2007529463A (ja)	2007-10-25
WO2005089786A3 (en)	2006-06-15
AU2005224028A1 (en)	2005-09-29

Legal Events

Date	Code	Title	Description
2011-06-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE519495T1 (de)	2011-08-15	Y4-selektiver rezeptoragonist pp2-36 für therapeutische eingriffe
DK1734971T3 (da)	2012-02-13	Indretning på polymerbasis med forsinket frigivelse
DE60317677D1 (de)	2008-01-03	Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
ATE516301T1 (de)	2011-07-15	Y2-selektive rezeptoragonisten für therapeutische eingriffe
DE602005015577D1 (de)	2009-09-03	Harnstoff-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
DK2119715T3 (da)	2012-09-10	Benzimidazolderivat og dets anvendelse som AII-receptorantagonisk
CL2008003847A1 (es)	2009-11-27	Compuestos derivados de 6-fenilpirazin-2-carboxamida y 6-fenilpirazin-2-carbotioamida, inhibidores de dgat-1; composicion farmaceutica; y su uso en el tratamiento de la diabetes mellitus y obesidad.
ATE490239T1 (de)	2010-12-15	Substituierte phenylpiperidinderivate als melanocortin-4-rezeptormodulatoren
GEP20094844B (en)	2009-11-25	3-aminocyclopentane carboxamides as modulators of chemokine receptors
NO20084006L (no)	2008-09-26	Modulatorer av muskarinreseptorer
NO20082345L (no)	2008-05-23	Selektive VPAC2 reseptorpeptidagonister
EP2272524A3 (de)	2011-02-02	Y2-selektive Rezeptor Agonisten und ihre therapeutische Verwendung
DK2059508T3 (da)	2012-07-23	5,6-bisaryl-2-pyridin-carboxamidderivater, fremstilling deraf og terapeutisk anvendelse deraf som urotensin II-receptorantagonister
GEP20094843B (en)	2009-11-25	3-aminocyclopentane carboxamides as modulators of chemokine receptors
MA28580B1 (fr)	2007-05-02	3-(4-hétéroarylcyclohexylamino) cyclopentanecarboxamides servant de modulateurs de récepteurs de chimiokines
ATE484506T1 (de)	2010-10-15	Substituierte diazepin-sulfonamide als bombesin- rezeptor-subtyp-3-modulatoren
EA200802104A1 (ru)	2009-04-28	Применение композиций, содержащих антагонисты каппа-опиоидных рецепторов, для лечения диссоциативных расстройств
ATE519498T1 (de)	2011-08-15	Kombination aus somatostatin-analoga unterschiedlicher selektivität für humane somatostatin-rezeptor-subtypen
EP1755603A4 (de)	2009-03-11	3,3-disubstituierte tetrahydropyranyl cyclopentyl amide modulatoren der chemokin-rezeptor-aktivität
EP1751175A4 (de)	2008-12-17	Antagonisten des interleukin-1-rezeptors, zusammensetzungen und behandlungsverfahren
DE602005005298D1 (de)	2008-04-24	1-benzyl-5-piperazin-1-yl-3,4 dihydro-1h-chinazolin-2-on-derivate und die jeweiligen 1h-benzo(1,2,6)thiadiazin-2,2-dioxid und 1,4-dihydro-benzo(d)(1,3)oxazin-2-on-derivate als modulatoren des 5-hydroxytryptamin-rezeptors (5-ht) zur behandlung von erk
ATE460404T1 (de)	2010-03-15	Modulatoren von alpha7-nikotin-acetylcholin- rezeptoren und therapeutische anwendungen davon
EP1729857A4 (de)	2009-04-08	Feuerlöschverfahren, -vorrichtung und -mittel
DE602006010737D1 (de)	2010-01-07	3-(4-äÄ4-(4äÄ3-(3,3-DIMETHYL-1-PIPERIDINYL)PROPYLÄOXYÜPHINYLÜ-1-PIPERIDINYLCARBONYLü-1-NAPHTHALINYL)PROPAN- ODER PROPENSÄURE ALS H1- UND H3-REZEPTOR-ANTAGONISTEN ZUR BEHANDLUNG ENTZÜNDLICHER UND/ODER ALLERGISCHER ERKRANKUNGEN
DK1420789T3 (da)	2007-09-17	Anvendelse af aktivstoffer med my-opioid-receptoragonistisk virkning og opioid-receptorantagonistisk virkning som kombinationslægemidler til cancerbehandling